Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-dose vs Normal-dose Psychostimulants in ADHD
NCT02167048Phase 2Active, not recruiting
- Sponsor
- University of British Columbia
- Start
- Jun 2014
- Primary completion
- Dec 2024
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in attention deficit hyperactivity disorder (ADHD) (3 arms), sponsored by University of British Columbia. Primary endpoint: Executive Functions (difference in performance on the two Psychostimulants doses) at 2 weeks. Started Jun 2014; status: active, not recruiting.
02
Conditions
attention deficit hyperactivity disorder (ADHD)
Beyond the preview
Go deeper on NCT02167048.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02167048.